Calliditas Therapeutics AB Other Current Liabilities

Calliditas Therapeutics AB (CALT) currently reports a other current liabilities of $280M as of June 2024. That compares with $220M in the prior-year period — up 27.7% year over year. Use the charts on this page to explore Calliditas Therapeutics AB's other current liabilities history and peer comparisons.

Calliditas Therapeutics AB's other current liabilities increased from $220M to $280M — a 27.7% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Calliditas Therapeutics AB reported $280M in other current liabilities as of June 2024. That compares with $220M in the prior-year period — up 27.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $280M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Calliditas Therapeutics AB, and consider following CALT for alerts when major investors trade the stock.

Calliditas Therapeutics AB is classified in the Healthcare sector. On other current liabilities, it currently shows $280M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CALT with unrelated industries.